vs
Side-by-side financial comparison of Pineapple Financial Inc. (PAPL) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
China SXT Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($829.5K vs $707.3K, roughly 1.2× Pineapple Financial Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -2756.2%, a 2659.4% gap on every dollar of revenue. On growth, China SXT Pharmaceuticals, Inc. posted the faster year-over-year revenue change (0.0% vs -4.8%). China SXT Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.8M vs $-3.3M).
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
PAPL vs SXTC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $707.3K | $829.5K |
| Net Profit | $-19.5M | $-802.6K |
| Gross Margin | 48.9% | 16.2% |
| Operating Margin | -2518.8% | -76.9% |
| Net Margin | -2756.2% | -96.8% |
| Revenue YoY | -4.8% | 0.0% |
| Net Profit YoY | -3174.1% | 0.0% |
| EPS (diluted) | $-1.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $707.3K | — | ||
| Q4 25 | $721.7K | — | ||
| Q3 25 | $730.5K | $829.5K | ||
| Q2 25 | $746.9K | — | ||
| Q1 25 | $743.3K | — | ||
| Q4 24 | $766.1K | — | ||
| Q3 24 | $598.3K | $829.5K | ||
| Q2 24 | $736.4K | — |
| Q1 26 | $-19.5M | — | ||
| Q4 25 | $-6.4M | — | ||
| Q3 25 | $-1.8M | $-802.6K | ||
| Q2 25 | $-557.7K | — | ||
| Q1 25 | $-595.4K | — | ||
| Q4 24 | $-656.9K | — | ||
| Q3 24 | $-1.7M | $-802.6K | ||
| Q2 24 | $-848.6K | — |
| Q1 26 | 48.9% | — | ||
| Q4 25 | 49.6% | — | ||
| Q3 25 | 27.8% | 16.2% | ||
| Q2 25 | 67.6% | — | ||
| Q1 25 | 43.4% | — | ||
| Q4 24 | 45.9% | — | ||
| Q3 24 | 43.2% | 16.2% | ||
| Q2 24 | 44.2% | — |
| Q1 26 | -2518.8% | — | ||
| Q4 25 | -909.1% | — | ||
| Q3 25 | -131.3% | -76.9% | ||
| Q2 25 | -93.3% | — | ||
| Q1 25 | -80.6% | — | ||
| Q4 24 | -90.5% | — | ||
| Q3 24 | -232.8% | -76.9% | ||
| Q2 24 | -121.7% | — |
| Q1 26 | -2756.2% | — | ||
| Q4 25 | -891.6% | — | ||
| Q3 25 | -250.3% | -96.8% | ||
| Q2 25 | -74.7% | — | ||
| Q1 25 | -80.1% | — | ||
| Q4 24 | -85.7% | — | ||
| Q3 24 | -283.9% | -96.8% | ||
| Q2 24 | -115.2% | — |
| Q1 26 | $-1.21 | — | ||
| Q4 25 | $-4.79 | — | ||
| Q3 25 | $-0.93 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $-1.73 | — | ||
| Q4 24 | $-2.60 | — | ||
| Q3 24 | $-11.10 | $-0.25 | ||
| Q2 24 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $27.1M | $15.4M |
| Total Assets | $48.9M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $18.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $18.5M | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $105.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — |
| Q1 26 | $27.1M | — | ||
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $906.7K | $15.4M | ||
| Q2 25 | $842.6K | — | ||
| Q1 25 | $739.7K | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $1.3M | $15.0M | ||
| Q2 24 | $2.0M | — |
| Q1 26 | $48.9M | — | ||
| Q4 25 | $10.6M | — | ||
| Q3 25 | $5.4M | $21.7M | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $4.0M | — | ||
| Q4 24 | $4.1M | — | ||
| Q3 24 | $4.1M | $31.0M | ||
| Q2 24 | $4.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-1.4M |
| Free Cash FlowOCF − Capex | $-3.3M | $-1.8M |
| FCF MarginFCF / Revenue | -462.7% | -216.2% |
| Capex IntensityCapex / Revenue | 0.0% | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-3.3M | — | ||
| Q4 25 | $-489.7K | — | ||
| Q3 25 | $-507.6K | $-1.4M | ||
| Q2 25 | $397.0K | — | ||
| Q1 25 | $-172.6K | — | ||
| Q4 24 | $-663.6K | — | ||
| Q3 24 | $-264.7K | $-1.4M | ||
| Q2 24 | $123.0K | — |
| Q1 26 | $-3.3M | — | ||
| Q4 25 | $-491.7K | — | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-264.7K | — | ||
| Q2 24 | $122.7K | — |
| Q1 26 | -462.7% | — | ||
| Q4 25 | -68.1% | — | ||
| Q3 25 | — | -216.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -44.2% | — | ||
| Q2 24 | 16.7% | — |
| Q1 26 | 0.0% | — | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
